Literature DB >> 8593783

Tumorigenic and mitogenic capacities are reduced in transfected fibroblasts expressing mutant insulin-like growth factor (IGF)-I receptors. The role of tyrosine residues 1250, 1251, and 1316 in the carboxy-terminus of the IGF-I receptor.

V A Blakesley1, T Kalebic, L J Helman, B Stannard, T N Faria, C T Roberts, D LeRoith.   

Abstract

Regulation of ligand-mediated signal transduction through transmembrane tyrosine kinase growth factor receptors involves phosphorylation of tyrosine residues in the intracellular domain of the receptor. The insulin-like growth factor-I (IGF-I) receptor contains three tyrosine residues in the carboxy-terminal domain at positions 1250, 1251, and 1316. Of these, only the tyrosine at position 1316 is conserved in the homologous position of the insulin receptor. Mutational analysis was used to study the role of these tyrosines in specific outcomes of IGF-I-mediated signal transduction. Mutations in the human IGF-I receptor were either replacement of tyrosines 1250 and 1251 with phenylalanine and histidine (yyFH), respectively, or replacement of the conserved distal tyrosine (position 1316) with phenylalanine (yCF). The yyFH mutation results in an IGF-I receptor with the amino acids found in the homologous position of the human insulin receptor. Cells overexpressing mutated IGF-I receptors were compared with cells expressing only endogenous IGF-I receptors or overexpressing wild-type IGF-I receptors. The ability of yyFH mutant IGF-I receptors to autophosphorylate the beta-subunit or phosphorylate insulin receptor substrate-1 was not significantly different from wild-type type IGF-I receptors. However, one or both of the proximal tyrosine residues (positions 1250 and 1251) in the carboxy-terminus of the IGF-I receptor are essential for IGF-I-stimulation of mitogenic and tumorigenic pathways. IGF-I-induced mitogenesis, measured as thymidine incorporation and cellular proliferation, was abrogated in cells overexpressing mutant IGF-I receptors with replacement of the proximal double tyrosines (positions 1250 and 1251). Fibroblasts expressing this mutant IGF-I receptor formed fewer tumors than the negative control cells, whereas cells expressing wild-type IGF-I receptors formed large tumors in all recipient mice injected. Conversely, cells expressing mutant IGF-I receptors with only the conserved distal tyrosine (position 1316) replaced had slightly reduced IGF-I-stimulated beta-subunit autophosphorylation, thymidine incorporation, and cellular proliferation when compared with cells expressing wild-type receptors. Phosphorylation of insulin receptor substrate-1 by the yCF mutant receptors was not impaired. Despite the ability of these mutant receptors to stimulate mitogenic growth, fibroblasts expressing this mutant receptor were also incapable of forming tumors in recipient nude mice. The distal tyrosine (position 1316) of the IGF-I receptor is crucial for tumor formation but is not essential for IGF-I stimulated mitogenesis. Thus, the tyrosine moieties in the carboxy-terminus of the IGF-I receptor participate in the signal transduction pathways that affect the mitogenic and tumorigenic potentials of cells expressing mutant IGF-I receptors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8593783     DOI: 10.1210/endo.137.2.8593783

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  8 in total

1.  Ethanol, Zn2+ and insulin interact as progression factors to enhance DNA synthesis synergistically in the presence of Ca2+ and other cell cycle initiators in fibroblasts.

Authors:  J S Huang; Q B She; K S Crilly; Z Kiss
Journal:  Biochem J       Date:  2000-02-15       Impact factor: 3.857

2.  Type-1 insulin-like growth factor receptor reexpression in the malignant phenotype of SV40-T-immortalized human prostate epithelial cells enhances apoptosis.

Authors:  S S Plymate; V L Bae; L Maddison; L S Quinn; J L Ware
Journal:  Endocrine       Date:  1997-08       Impact factor: 3.633

3.  14-3-3 proteins interact with the insulin-like growth factor receptor but not the insulin receptor.

Authors:  R W Furlanetto; B R Dey; W Lopaczynski; S P Nissley
Journal:  Biochem J       Date:  1997-11-01       Impact factor: 3.857

4.  Interaction in vitro of the product of the c-Crk-II proto-oncogene with the insulin-like growth factor I receptor.

Authors:  A P Koval; V A Blakesley; C T Roberts; Y Zick; D Leroith
Journal:  Biochem J       Date:  1998-03-01       Impact factor: 3.857

5.  Serine phosphorylation of the insulin-like growth factor I (IGF-1) receptor C-terminal tail restrains kinase activity and cell growth.

Authors:  Geraldine M Kelly; Deirdre A Buckley; Patrick A Kiely; David R Adams; Rosemary O'Connor
Journal:  J Biol Chem       Date:  2012-06-08       Impact factor: 5.157

6.  Phosphatidylinositol 3-kinase (PI3K) activity bound to insulin-like growth factor-I (IGF-I) receptor, which is continuously sustained by IGF-I stimulation, is required for IGF-I-induced cell proliferation.

Authors:  Toshiaki Fukushima; Yusaku Nakamura; Daisuke Yamanaka; Takashi Shibano; Kazuhiro Chida; Shiro Minami; Tomoichiro Asano; Fumihiko Hakuno; Shin-Ichiro Takahashi
Journal:  J Biol Chem       Date:  2012-07-05       Impact factor: 5.157

7.  Phytosterol Pygeum africanum regulates prostate cancer in vitro and in vivo.

Authors:  Nader S Shenouda; Mary S Sakla; Leslie G Newton; Cynthia Besch-Williford; Norman M Greenberg; Ruth S MacDonald; Dennis B Lubahn
Journal:  Endocrine       Date:  2007-02       Impact factor: 3.633

8.  Molecular basis of signaling specificity of insulin and IGF receptors: neglected corners and recent advances.

Authors:  Kenneth Siddle
Journal:  Front Endocrinol (Lausanne)       Date:  2012-02-28       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.